PepGen
PEPGPEPG · Stock Price
Historical price data
Overview
PepGen is a clinical-stage biotech focused on developing transformative oligonucleotide therapies for severe genetic neuromuscular and neurological diseases. Its core strategy leverages a proprietary Enhanced Delivery Oligonucleotide (EDO) platform designed to solve the critical challenge of delivering therapeutic cargo to deep tissues like muscle and nerve cells. The company's lead candidate, PGN-EDODM1 for myotonic dystrophy type 1 (DM1), has generated compelling early clinical data, including unprecedented splicing correction, and is advancing in Phase 2 studies. With a modular platform and a pipeline extending into Duchenne muscular dystrophy (DMD) and Charcot-Marie-Tooth disease (CMT1A), PepGen aims to establish a new class of disease-modifying genetic medicines.
Technology Platform
Proprietary Enhanced Delivery Oligonucleotide (EDO) platform, featuring engineered cell-penetrating peptides conjugated to therapeutic oligonucleotides to enable efficient, deep-tissue delivery to muscle and nerve cells.
Pipeline
5| Drug | Indication | Stage | Watch |
|---|---|---|---|
| PGN-EDODM1 | Myotonic Dystrophy 1 | Phase 2 | |
| PGN-EDODM1 | Myotonic Dystrophy 1 | Phase 2 | |
| IV infusion | Duchenne Muscular Dystrophy (DMD) | Phase 2 | |
| PGN-EDO51 | Duchenne Muscular Dystrophy | Phase 2 | |
| PGN-EDODM1 for infusion | Myotonic Dystrophy 1 | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
PepGen faces direct competition in DM1 from companies like Avidity Biosciences and Dyne Therapeutics, which are also developing conjugate-based oligonucleotide delivery platforms. In DMD, it competes in a crowded market with approved exon-skipping drugs. PepGen's competitive edge hinges on its EDO platform's specific design and early data showing exceptional muscle uptake and target engagement in DM1.